Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTPRC | P08575 | 4/20 | 1.00 |
| ▸ | TTR | P02766 | 6/20 | 0.81 |
| ▸ | S100A4 | P26447 | 1/20 | 0.70 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.62 |
| ▸ | POLB | P06746 | 1/20 | 0.62 |
| ▸ | MAPT | P10636 | 3/20 | 0.60 |
| ▸ | MEN1 | O00255 | 2/20 | 0.60 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.60 |
| ▸ | HPGD | P15428 | 1/20 | 0.60 |
| ▸ | CDC25A | P30304 | 1/20 | 0.60 |
| ▸ | CDC25B | P30305 | 1/20 | 0.60 |
| ▸ | CTDSP1 | Q9GZU7 | 1/20 | 0.60 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.60 |
| ▸ | CHEK1 | O14757 | 1/20 | 0.60 |
| ▸ | CTSL | P07711 | 1/20 | 0.57 |
| ▸ | PTPN13 | Q12923 | 1/20 | 0.57 |
| ▸ | NPC1 | O15118 | 2/20 | 0.55 |
| ▸ | LMNA | P02545 | 2/20 | 0.55 |
| ▸ | RAB9A | P51151 | 2/20 | 0.55 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.55 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6261915 | 0.96 | PTPRC (1.00) | PTPRCTTRS100A4KMT2APOLB | |
| SCHEMBL3100326 | 0.96 | PTPRC (0.92) | PTPRCTTRS100A4KMT2APOLB | |
| SCHEMBL292802 | 0.92 | TTR (0.96) | PTPRCTTRS100A4KMT2APOLB | |
| SCHEMBL503529 | 0.92 | PTPRC (0.84) | PTPRCTTRS100A4KMT2APOLB | |
| SCHEMBL30610011 | 0.90 | TTR (1.00) | PTPRCTTRS100A4KMT2APOLB | |
| SCHEMBL123492 | 0.90 | TTR (1.00) | PTPRCTTRS100A4KMT2APOLB | |
| Hydrochloric Acid SCHEMBL10688924 | 0.90 | PTPRC (0.81) | PTPRCTTRS100A4KMT2APOLB | |
| SCHEMBL11877439 | 0.88 | TTR (0.96) | PTPRCTTRS100A4KMT2APOLB | |
| SCHEMBL29917994 | 0.88 | TTR (0.96) | PTPRCTTRS100A4KMT2APOLB | |
| SCHEMBL28446002 | 0.88 | TTR (0.96) | PTPRCTTRS100A4KMT2APOLB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 22 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1242363-B1 | CD45 INHIBITORS | ASTRAZENECA AB (SE) | 2005-11-02 | — | — | EP | claimed |
| US-20030207812-A1 | Cd45 inhibitors | ASTRAZENECA AB (SE) | 2003-11-06 | — | — | US | claimed |
| JP-2003518085-A | — | — | 2003-06-03 | — | — | JP | claimed |
| EP-1242363-A2 | CD45 INHIBITORS | AstraZeneca AB (SE) | 2002-09-25 | — | — | EP | claimed |
| WO-2001046125-A2 | CD45 INHIBITORS | ASTRAZENECA AB (SE) | 2001-06-28 | — | — | WO | claimed |
| WO-2024130526-A1 | A BIOORTHOGONAL CYCLOADDITION REACTION AND USE THEREOF | NANJING UNIVERSITY (CN) | 2024-06-27 | — | — | WO | disclosed |
| US-20200155609-A1 | COMPOSITIONS AND METHODS OF MAKING EXPANDED HEMATOPOIETIC STEM CELLS USING PTEN INHIBITORS | TRANSFUSION HEALTH LLC | 2020-05-21 | — | — | US | disclosed |
| US-10164258-B2 | Fused-ring quinone-substituted polynorbornene, electrode active material and secondary battery | WASEDA UNIVERSITY (JP) | 2018-12-25 | — | — | US | disclosed |
| US-20170104214-A1 | FUSED-RING QUINONE-SUBSTITUTED POLYNORBORNENE, ELECTRODE ACTIVE MATERIAL AND SECONDARY BATTERY | WASEDA UNIVERSITY (JP) | 2017-04-13 | — | — | US | disclosed |
| US-20170104214-A1 | FUSED-RING QUINONE-SUBSTITUTED POLYNORBORNENE, ELECTRODE ACTIVE MATERIAL AND SECONDARY BATTERY | WASEDA UNIVERSITY (JP) | 2017-04-13 | — | — | US | disclosed |
| US-20170104214-A1 | FUSED-RING QUINONE-SUBSTITUTED POLYNORBORNENE, ELECTRODE ACTIVE MATERIAL AND SECONDARY BATTERY | WASEDA UNIVERSITY (JP) | 2017-04-13 | — | — | US | disclosed |
| WO-2009106779-A2 | NOVEL PHOTOSENSITISING MOLECULES DERIVED FROM 9,10-DICYANOANTHRACENE, METHOD FOR PREPARING SAME AND USES THEREOF | UPPA - UNIVERSITÉ DE PAU ET DES PAYS DE L'ADOUR (FR) | 2009-09-03 | — | — | WO | disclosed |
| US-20030207812-A1 | Cd45 inhibitors | ASTRAZENECA AB (SE) | 2003-11-06 | — | — | US | disclosed |
| EP-1242363-A2 | CD45 INHIBITORS | AstraZeneca AB (SE) | 2002-09-25 | — | — | EP | disclosed |
| WO-2001046125-A2 | CD45 INHIBITORS | ASTRAZENECA AB (SE) | 2001-06-28 | — | — | WO | disclosed |
| EP-0820483-B1 | METHOD OF PHOTOCHEMICAL IMMOBILIZATION OF LIGANDS USING QUINONES | JAKOBSEN MOGENS HAVSTEEN (DK) | 2000-12-13 | — | — | EP | disclosed |
| US-6033784-A | Method of photochemical immobilization of ligands using quinones | JAKOBSEN MOGENS HAVSTEEN (DK) | 2000-03-07 | — | — | US | disclosed |
| EP-0820483-A1 | METHOD OF PHOTOCHEMICAL IMMOBILIZATION OF LIGANDS USING QUINONES | Jakobsen, Mogens Havsteen (DK) | 1998-01-28 | — | — | EP | disclosed |
| WO-1996031557-A1 | METHOD OF PHOTOCHEMICAL IMMOBILIZATION OF LIGANDS USING QUINONES | JACOBSEN MOGENS HAVSTEEN (DK) | 1996-10-10 | — | — | WO | disclosed |
| US-4302527-A | BIS/9,10-PHENANTHRONE-3-CARBOXYLATES/AS PHOTOINITIATORS; PHOTOPOLYMERIZATION; LITHOGRAPHY; PHOTORESISTS; COATINGS | EASTMAN KODAK COMPANY (US) | 1981-11-24 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030207812-A1 | Cd45 inhibitors | CD74, CD2, PTPRC | PTPRC 3/4885TTR 298/4885S100A4 2288/4885 |
| US-20200155609-A1 | COMPOSITIONS AND METHODS OF MAKING EXPANDED HEMATOPOIETIC STEM CELLS USING PTEN INHIBITORS | PTEN, MCL1, PIK3CA | PTPRC 20/4885TTR 4614/4885S100A4 4173/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.